Spevigo intravenous infusion 450 mg, manufactured by Nippon Boehringer Ingelheim, contains spesolimab (genetical recombination). Spesolimab is an interleukin-36 receptor (IL-36R) antagonist indicated for the treatment of generalized pustular psoriasis (GPP) flares in adults and children 12 years of age and older weighing at least 40 kg. It is administered via intravenous infusion and supplied as a 450mg/7.5mL/1 bottle injectable drug (YJ code: 3999466A1026).
Spevigo intravenous infusion 450 mg
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).
